News

BÜHLMANN Laboratories AG (“BÜHLMANN”) announces the closing of the acquisition by funds advised by KLAR Partners Limited (“KLAR Partners” or “KLAR”) today June 5th, 2024. The acquisition enables BÜHLMANN to support its future as a leading independent specialty in-vitro diagnostics company.

Discover the latest advancements from the EAACI 2023 Congress in Hamburg, featuring three insightful posters on the Basophil Activation Test. Topics include validation studies, technical cut-offs, and automated gating strategies.

From gastroenterology to neuroimmunology, read the newest developments from BÜHLMANN in our posters presented at the WorldLab 2024!

During ECCO 2024, held from February 21st to 24th, international IBD specialists came to Stockholm to present the latest news in IBD care. In this setting, our colleagues Oliver Dähn and Christian Reinhard had the privilege of presenting the following two posters:   Poster 1: P437 - Feasibility study of a Point-of-Care assay for rapid